论文部分内容阅读
美国圣迭戈消息;血小板抑制剂乙酰水杨酸(ASA)和哌醇定(DP)联合应用使在欧洲卒中预防研究(ESPS)中接受治疗的高危病人死亡率及反复的卒中发病率明显下降。研究人员指出,与安慰剂对照相比,治疗的病人的总死亡率及卒中发病率低33%。此项双盲、随机试验包括在欧洲及英国16个中心治疗的1861名病人.该试验是为了验证以下假设而特别设计的,即改变血小板的功能可能有利于预防患脑血管疾病的血栓-栓塞病人继发卒中或死亡。 ESPS病人在开始进入研究的3个月内均有脑血管疾病,这些疾病的范围为一过性缺血
San Diego, USA; The combination of the platelet inhibitors acetylsalicylic acid (ASA) and piperdin (DP) markedly reduced the risk of death and recurrent stroke in high-risk patients treated in the European Stroke Prevention Study (ESPS). The researchers noted that the treated patients had a 33% lower overall rate of death and stroke compared with placebo. This double-blind, randomized trial includes 1,861 patients treated in 16 centers in Europe and the UK This test was specifically designed to test the hypothesis that altering platelet function may be beneficial in preventing thromboembolism in patients with cerebrovascular disease Patient secondary to stroke or death. ESPS patients have cerebrovascular disease within 3 months of starting the study, and the range of these diseases is transient ischemia